Lidocaine gel preparation

A lidocaine gel formulation with hydroxypropyl cellulose and propylene glycol addresses skin irritation and crystallization issues, ensuring high absorption and efficacy for patients with postherpetic neuralgia.

JP2024158843APending Publication Date: 2024-11-08TEIKOKU SEIYAKU CO LTD
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
JP2023074407
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-04-28
Publication Date
2024-11-08

Smart Images

  • Figure 2024158843000007
    Figure 2024158843000007
  • Figure 2024158843000001
    Figure 2024158843000001
  • Figure 2024158843000002
    Figure 2024158843000002
Patent Text Reader

Abstract

To provide a lidocaine-containing gel preparation characterized by high percutaneous absorption of lidocaine and low skin irritation.SOLUTION: A gel preparation contains lidocaine or a pharmaceutically acceptable salt thereof, a water-soluble polymer, glycerol, and propyleneglycol in an amount of 40 wt.% or more relative to the preparation weight. The gel preparation is free of water and C1-4 alcohols.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a gel preparation containing lidocaine, and more particularly to a gel preparation which exhibits excellent skin permeability of lidocaine and is highly safe to the skin. [Background technology]

[0002] Lidocaine was developed as a local anesthetic and has surface, infiltrative and conduction anesthetic properties. It is used mainly for surface anesthesia in the dental field, and is also widely used as the first-choice drug for the treatment of ventricular arrhythmias associated with premature ventricular contractions, acute myocardial infarction and cardiac surgery. Lidocaine is also used as an external preparation for postherpetic neuralgia, and is currently available in the form of an aqueous patch in many countries around the world, but no ointment or gel formulations for postherpetic neuralgia are currently available on the market.

[0003] Since the skin of patients with postherpetic neuralgia is often damaged, in the case of gel preparations containing highly skin-irritating base components, there is a risk that the components will irritate the patient's skin and cause pain, so it is necessary to select a base with low irritation. In particular, lower alcohols such as ethanol and isopropanol, which are often used as base components in gel preparations, are excellent at promoting the absorption of drug components, but they are likely to induce skin irritation, so their inclusion in gel preparations must be carefully considered.

[0004] On the other hand, various studies have been conducted on topical preparations containing lidocaine, and as mentioned above, technologies related to ointments, creams, jellies, sprays, etc., as well as patches, have been reported. Patent Document 1 describes a topical preparation containing 20-40% high-concentration lidocaine. The present invention is characterized in that the active ingredient lidocaine is released in an initial burst in less than 6 hours, but there is a concern that the active ingredient may crystallize during storage. In addition, the skin topical preparations in Patent Document 2 and Patent Document 3 contain lower alcohol, and there remains a concern of skin irritation when used by patients with postherpetic neuralgia. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] Special Publication No. 2010-536793 [Patent Document 2] Special Publication No. 2001-503035 [Patent Document 3] Patent Publication No. 2021-91655 Summary of the Invention [Problem to be solved by the invention]

[0006] Therefore, an object of the present invention is to provide a gel preparation containing lidocaine which solves the above-mentioned conventional problems and has high percutaneous absorbability of lidocaine and low skin irritation. [Means for solving the problem]

[0007] In order to solve such problems, the present inventors have conducted extensive research and found that a gel formulation having excellent percutaneous absorption of lidocaine and low skin irritation can be obtained by blending lidocaine or a medicamentically acceptable salt thereof with a base that does not contain water or lower alcohol and contains a water-soluble polymer, glycerin, and propylene glycol in an amount of 40% by weight or more based on the weight of the formulation as essential ingredients. More preferably, the gel formulation is one in which the water-soluble polymer is hydroxypropyl cellulose. Even more preferably, the gel formulation is one in which 1-20% by weight of lidocaine or a medicamentically acceptable salt thereof is blended with a base containing 0.5-5% by weight of a water-soluble polymer, 10-40% by weight of glycerin, and 40-80% by weight of propylene glycol based on the weight of the formulation.

[0008] That is, the present invention relates to the following. [1] A gel formulation comprising lidocaine or a pharma- ceutical acceptable salt thereof, a water-soluble polymer, glycerin, and 40% or more by weight of propylene glycol relative to the weight of the formulation, and not containing water or a C1-4 alcohol (hereinafter also referred to as the gel formulation of the present invention). [2] The gel formulation described in [1], wherein the lidocaine or a pharma- ceutical acceptable salt thereof is lidocaine in a non-salt form. [3] The gel formulation according to [1] or [2], wherein the water-soluble polymer is one or more selected from the group consisting of polyacrylic acid, polyacrylates, partially neutralized polyacrylic acids, sodium carmellose, gelatin, methyl vinyl ether-maleic anhydride copolymers, N-vinylacetamide copolymers, sodium alginate, polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl methacrylate, polyethylene oxide, carboxyvinyl polymers, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, ethylcellulose, starch-acrylic acid graft copolymers, carrageenan, sodium alginate, agar, acacia gum, guar gum, xanthan gum, gum arabic, karaya gum, tragacanth gum, and collagen. [4] The gel formulation according to [1] or [2], wherein the water-soluble polymer is one or more selected from the group consisting of carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, and ethylcellulose. [5] The gel formulation according to [1] or [2], wherein the water-soluble polymer is hydroxypropyl cellulose. [6] 1. A gel formulation according to any one of [1] to [5], comprising, relative to the weight of the formulation, 1 to 20% by weight of lidocaine or a pharma- ceutical acceptable salt thereof, 0.5 to 5% by weight of a water-soluble polymer, 10 to 40% by weight of glycerin, and 40 to 80% by weight of propylene glycol. [7] The gel formulation according to any one of [1] to [6], wherein the weight ratio of propylene glycol to glycerin is within the range of propylene glycol:glycerin=1:1 to 7:1. [8] The gel formulation according to any one of [1] to [7], further comprising one or more additional components selected from the group consisting of 1,3-butanediol, oleic acid, isopropyl myristate, glycerin triisooctanoate, crotamiton, diethyl sebacate, diisopropyl adipate, and hexyl laurate. [9] The gel formulation according to any one of [1] to [7], further comprising one or two additional components selected from the group consisting of oleic acid and isopropyl myristate.

[10] The gel formulation according to [8] or [9], comprising an additional component in an amount of 0.5 to 15% by weight based on the weight of the formulation.

[11] The gel formulation according to any one of [1] to

[10] , for inducing local anesthesia, or for preventing or treating arrhythmia or pain.

[12] The gel formulation according to any one of [1] to

[10] , for preventing or treating postherpetic neuralgia. Effect of the Invention

[0009] The present invention makes it possible to provide a lidocaine gel that exhibits high percutaneous absorption of lidocaine and low skin irritation. The present invention exhibits low irritation even in patients with postherpetic neuralgia, many of whom suffer from skin damage, and is therefore extremely effective in improving the QOL of such patients. [Brief description of the drawings]

[0010] [Figure 1] FIG. 1 is a graph showing the results of the pinprick test in Test Example 3. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] The lidocaine gel formulation of the present invention will be described in further detail below. The lidocaine gel formulation of the present invention may also be referred to as a "lidocaine gel composition", "lidocaine gel", "gel formulation", "gel composition", or the like.

[0012] In this specification, the terms "contain" and "include" may be used interchangeably with "blended." In addition, in this specification, the terms "content" and "blended amount" may be used interchangeably.

[0013] The gel formulation of the present invention does not contain water or a C1-4 alcohol (also referred to as a "lower alcohol"), and contains lidocaine or a pharma- ceutically acceptable salt thereof in a gel base that contains, as essential components, a water-soluble polymer, glycerin, and propylene glycol in an amount of 40% by weight or more relative to the weight of the formulation, thereby providing a gel formulation that has high transdermal absorbability of lidocaine and low skin irritation.

[0014] The gel preparation of the present invention may contain lidocaine in a non-salt form or a pharma- tically acceptable salt of lidocaine depending on the base component. Examples of pharma- tically acceptable salts of lidocaine include hydrochloride (lidocaine hydrochloride). The gel preparation of the present invention preferably contains lidocaine in a non-salt form.

[0015] The amount of the active ingredient lidocaine or a pharma- ceutical acceptable salt thereof is usually 1-20% by weight, preferably 3-20% by weight, more preferably 5-15% by weight, based on the weight of the formulation. If the amount of lidocaine is less than 1% by weight, the desired analgesic effect cannot be obtained. If the amount of lidocaine is more than 20% by weight, undesirable effects such as crystallization of lidocaine in the formulation or deterioration of the formulation properties occur.

[0016] Propylene glycol acts as a dissolving agent for lidocaine. In the present invention, the amount of propylene glycol is 40% by weight or more, preferably 40 to 80% by weight, more preferably 40 to 70% by weight, and even more preferably 40 to 60% by weight, based on the weight of the preparation. If the amount of propylene glycol is less than 40% by weight, the solubility of lidocaine in the base decreases, and lidocaine crystals precipitate. If the amount of propylene glycol is more than 80% by weight, skin irritation increases.

[0017] Glycerin adjusts the gel viscosity of the present invention and has the function of suppressing skin irritation. In the present invention, the amount of glycerin is preferably 10 to 40% by weight, more preferably 20 to 40% by weight, and even more preferably 25 to 40% by weight, based on the weight of the formulation. If the amount of glycerin is less than 10% by weight, the physical properties of the formulation deteriorate and skin irritation increases. On the other hand, if the amount of glycerin is more than 40% by weight, the solubility of lidocaine in the base decreases, and undesirable effects such as precipitation of lidocaine crystals occur.

[0018] The blending ratio (weight ratio) of propylene glycol to glycerin in the present invention is preferably propylene glycol:glycerin=1:1 to 7:1, more preferably 6:5 to 2:1. When the ratio of propylene glycol to glycerin exceeds 1:1 and a large amount of glycerin is blended, crystals of lidocaine are precipitated. When the ratio exceeds 7:1 and a large amount of propylene glycol is blended, skin irritation increases.

[0019] Examples of water-soluble polymers to be incorporated in the present invention include polyacrylic acid, polyacrylates, partially neutralized polyacrylic acid, sodium carmellose, gelatin, methyl vinyl ether-maleic anhydride copolymer, N-vinylacetamide copolymer, sodium alginate, polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl methacrylate, polyethylene oxide, carboxyvinyl polymer, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, ethylcellulose, starch-acrylic acid graft copolymer, carrageenan, sodium alginate, agar, acacia gum, guar gum, xanthan gum, gum arabic, karaya gum, tragacanth gum, and collagen. These may be incorporated alone or in combination of two or more kinds. Preferably, one or more kinds selected from the group consisting of carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, and ethylcellulose are used, and hydroxypropylcellulose is more preferred.

[0020] The amount of the water-soluble polymer to be added is preferably 0.5 to 5% by weight, more preferably 0.5 to 3% by weight, and further preferably 1 to 2% by weight, based on the weight of the preparation.

[0021] The gel preparation of the present invention does not require the incorporation of water and lower alcohol, but these components contained in small amounts in each base raw material or remaining may be contained in the gel preparation of the present invention. In addition, water and lower alcohol mixed in small amounts during the manufacturing process may also be contained in the gel preparation of the present invention. That is, the gel preparation of the present invention does not substantially contain water and lower alcohol, but water and lower alcohol may remain or be mixed in small amounts during the manufacturing process, and such gel preparations containing water and lower alcohol remaining or mixed in small amounts are also included in the scope of the present invention as long as they do not affect the physical properties of the preparation.

[0022] The C1-4 alcohol (i.e., lower alcohol) that is not incorporated in the gel formulation of the present invention means a linear or branched alcohol having 1 to 4 carbon atoms, and examples of such alcohol include methanol, ethanol, n-propanol, isopropanol, n-butanol, sec-butanol, and tert-butanol.

[0023] In addition, the gel preparation of the present invention may further contain additional components such as bases such as white petrolatum, yellow petrolatum, lanolin, white beeswax, cetanol, stearyl alcohol, stearic acid, hardened oils, gelling hydrocarbons, polyethylene glycol, liquid paraffin, and squalane; solvents and solubilizing agents such as 1,3-butanediol, oleic acid, isopropyl myristate, glycerin triisooctanoate, crotamiton, diethyl sebacate, diisopropyl adipate, hexyl laurate, fatty acids, fatty acid esters, aliphatic alcohols, and vegetable oils; antioxidants such as tocopherol derivatives, L-ascorbic acid, dibutylhydroxytoluene, and butylhydroxyanisole; preservatives such as parahydroxybenzoic acid esters; moisturizers such as sodium hyaluronate; and surfactants such as polyoxyethylene derivatives, glycerin fatty acid esters, sucrose fatty acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters, and lecithin. The additional component is preferably one or more selected from the group consisting of 1,3-butanediol, oleic acid, isopropyl myristate, glycerin triisooctanoate, crotamiton, diethyl sebacate, diisopropyl adipate, and hexyl laurate, more preferably one or two selected from the group consisting of oleic acid and isopropyl myristate. The amount of the additional component is 0.5 to 15% by weight, preferably 1 to 10% by weight, more preferably 2 to 7% by weight, based on the weight of the formulation.

[0024] Furthermore, the gel preparation of the present invention may contain stabilizers, preservatives, absorption enhancers, pH adjusters and other suitable additives, if desired.

[0025] The gel preparation of the present invention contains lidocaine or a pharma- ceutical acceptable salt thereof as a medicinal ingredient, and is therefore useful for various diseases or symptoms that can be prevented or treated by lidocaine. More specifically, the gel preparation of the present invention is useful for inducing local anesthesia (e.g., surface anesthesia, infiltration anesthesia, conduction anesthesia, epidural anesthesia, spinal anesthesia, etc.), and for preventing or treating arrhythmia (e.g., ventricular arrhythmia) and pain (e.g., postherpetic neuralgia, etc.).

[0026] In the present invention, "prevention" refers to the administration of the gel preparation of the present invention to an individual who has not developed a disease or symptom. "Treatment" refers to the administration of the gel preparation of the present invention to an individual who has already developed a disease or symptom. Therefore, the administration of the gel preparation to an individual who has already developed a disease or symptom to prevent the worsening of symptoms, prevent attacks, or prevent recurrence is one aspect of "treatment".

[0027] The gel formulation of the present invention is usually administered to a patient, such as a human or animal, suffering from or at risk of the above-mentioned disease or condition, preferably to a human. The number of administrations may vary depending on conditions such as the severity of the disease or condition, the age, weight, and sex of the patient, and the amount of lidocaine or a pharma- ceutical acceptable salt thereof in the gel formulation. When administered to a human, the gel formulation of the present invention is usually applied once or multiple times a day, for example, 1 to 5 times, 1 to 3 times, or once a day, or every few days, for example, once every 2 to 3 days.

[0028] The gel preparation of the present invention can be produced by a conventional method. For example, a water-soluble polymer is added to glycerin and stirred to obtain a base solution, and lidocaine or a pharma- ceutical acceptable salt thereof is separately dissolved in propylene glycol, and this liquid and the base solution are mixed and stirred to produce a gel preparation.

[0029] The following are embodiments of the present invention. The present invention also includes embodiments in which the following embodiments are arbitrarily selected and combined, and embodiments in which the following embodiments are arbitrarily selected and combined with any of the embodiments described in this specification.

[0030] 1. Gel Formulation [Aspect 1] A gel formulation of the present invention comprising lidocaine or a pharma- ceutical acceptable salt thereof, a water-soluble polymer, glycerin, and 40% by weight or more of propylene glycol based on the weight of the formulation, and containing no water or C1-4 alcohol. [Aspect 2] The gel formulation of the invention according to embodiment 1, wherein the lidocaine or a pharma- ceutically acceptable salt thereof is a non-salt form of lidocaine. [Aspect 3] 3. The gel formulation of the present invention according to embodiment 1 or 2, wherein the water-soluble polymer is one or more selected from the group consisting of polyacrylic acid, polyacrylates, partially neutralized polyacrylic acids, sodium carmellose, gelatin, methyl vinyl ether-maleic anhydride copolymers, N-vinylacetamide copolymers, sodium alginate, polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl methacrylate, polyethylene oxide, carboxyvinyl polymers, carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, ethylcellulose, starch-acrylic acid graft copolymers, carrageenan, sodium alginate, agar, acacia gum, guar gum, xanthan gum, gum arabic, karaya gum, tragacanth gum, and collagen. [Aspect 4] 3. The gel formulation of the present invention according to embodiment 1 or 2, wherein the water-soluble polymer is one or more selected from the group consisting of carboxymethylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, and ethylcellulose. [Aspect 5] 3. The gel formulation of the invention according to embodiment 1 or 2, wherein the water-soluble polymer is hydroxypropyl cellulose. [Aspect 6] 6. The gel formulation of the present invention according to any one of Aspects 1 to 5, comprising, relative to the weight of the formulation, 1 to 20% by weight of lidocaine or a pharma- ceutically acceptable salt thereof, 0.5 to 5% by weight of a water-soluble polymer, 10 to 40% by weight of glycerin, and 40 to 80% by weight of propylene glycol. [Aspect 7] 6. The gel formulation of the present invention according to any one of Aspects 1 to 5, comprising, relative to the weight of the formulation, 3 to 20% by weight of lidocaine or a pharma- ceutical acceptable salt thereof, 0.5 to 3% by weight of a water-soluble polymer, 20 to 40% by weight of glycerin, and 40 to 70% by weight of propylene glycol. [Aspect 8] 6. The gel formulation of the present invention according to any one of Aspects 1 to 5, comprising, relative to the weight of the formulation, 5 to 15% by weight of lidocaine or a pharma- ceutical acceptable salt thereof, 1 to 2% by weight of a water-soluble polymer, 25 to 40% by weight of glycerin, and 40 to 60% by weight of propylene glycol. [Aspect 9] The gel formulation of the present invention according to any one of Aspects 1 to 8, wherein the weight ratio of propylene glycol to glycerin is within the range of propylene glycol:glycerin=1:1 to 7:1. [Aspect 10] The gel formulation of the present invention according to any one of Aspects 1 to 8, wherein the weight ratio of propylene glycol to glycerin is within the range of propylene glycol:glycerin=6:5 to 2:1. [Aspect 11] 11. The gel formulation of the present invention according to any one of Aspects 1 to 10, comprising lidocaine or a pharma- ceutical acceptable salt thereof, a water-soluble polymer, glycerin, and propylene glycol. [Aspect 12] 12. The gel formulation of the invention according to embodiment 11, wherein the lidocaine or a pharma- ceutical acceptable salt thereof is lidocaine in non-salt form and the water soluble polymer is hydroxypropyl cellulose. [Aspect 13] 11. The gel formulation of the present invention according to any one of aspects 1 to 10, further comprising one or more additional components selected from the group consisting of 1,3-butanediol, oleic acid, isopropyl myristate, glyceryl triisooctanoate, crotamiton, diethyl sebacate, diisopropyl adipate, and hexyl laurate. [Aspect 14] 11. The gel formulation of the present invention according to any one of aspects 1 to 10, further comprising one or two additional ingredients selected from the group consisting of oleic acid and isopropyl myristate. [Aspect 15] 15. The gel formulation of the invention according to aspect 13 or 14, comprising 0.5 to 15% by weight of the additional ingredient based on the weight of the formulation. [Aspect 16] 15. The gel formulation of the invention according to aspect 13 or 14, comprising 1 to 10% by weight of the additional ingredient based on the formulation weight. [Aspect 17] 15. The gel formulation of the invention according to aspect 13 or 14, comprising 2 to 7% by weight of the additional ingredient based on the formulation weight. [Aspect 18] 18. The gel formulation of the present invention according to any one of Aspects 13 to 17, comprising lidocaine or a pharma- ceutical acceptable salt thereof, a water-soluble polymer, glycerin, propylene glycol, and an additional component. [Aspect 19] The gel formulation of the invention according to embodiment 18, wherein the lidocaine or a pharma- ceutical acceptable salt thereof is lidocaine in non-salt form, the water soluble polymer is hydroxypropyl cellulose, and the additional component is oleic acid or isopropyl myristate.

[0031] 2. Uses of gel formulations [Aspect 20] 20. The gel formulation of the invention according to any one of aspects 1 to 19 for the induction of local anesthesia, or for the prevention or treatment of arrhythmia or pain. [Aspect 21] 20. The gel formulation of the invention according to any one of aspects 1 to 19 for the prevention or treatment of postherpetic neuralgia. [Aspect 22] 20. Use of the gel formulation of the invention according to any one of aspects 1 to 19 in the manufacture of a medicament for the induction of local anesthesia, or for the prevention or treatment of arrhythmia or pain. [Aspect 23] 20. Use of the gel formulation of the invention according to any one of aspects 1 to 19 in the manufacture of a medicament for the prevention or treatment of postherpetic neuralgia. [Aspect 24] A method for inducing local anesthesia, or preventing or treating arrhythmia or pain, comprising administering to a patient a gel formulation of the present invention according to any one of aspects 1 to 19. [Aspect 25] A method for preventing or treating postherpetic neuralgia, comprising administering to a patient the gel formulation of the present invention according to any one of aspects 1 to 19. [Aspect 26] 20. Use of the gel formulation of the invention according to any one of aspects 1 to 19 in the induction of local anesthesia, or in the prevention or treatment of arrhythmia or pain. [Aspect 27] 20. Use of the gel formulation of the invention according to any one of aspects 1 to 19 in the prevention or treatment of post-herpetic neuralgia. EXAMPLES

[0032] The present invention will be described in detail below with reference to examples, but the present invention is not limited thereto. Note that numerical values ​​in the examples are in "wt %" unless otherwise specified.

[0033] Example 1 Hydroxypropyl cellulose was added to glycerin and stirred to prepare a base solution. Separately, lidocaine was dissolved in propylene glycol, and this liquid and the base solution were mixed by stirring to obtain the desired gel preparation. The composition of Example 1 is shown in Table 1.

[0034] (Examples 2 to 4) According to the formulation shown in Table 1, gel preparations were produced in the same manner as in Example 1, and gel preparations of Examples 2 to 4 were obtained.

[0035] Comparative Example 1 According to the formulation shown in Table 2, a gel preparation was produced in the same manner as in Example 1, and a gel preparation of Comparative Example 1 was obtained.

[0036] [Table 1]

[0037] [Table 2]

[0038] (Test Example 1: Gel properties) The gel properties immediately after production were observed for the preparations of Examples 1 to 4 and Comparative Example 1. The gel properties of each preparation were evaluated according to the following criteria. The results are shown in Tables 1 and 2. Good: No seepage of liquid ingredients, good shape retention, and easy application to the skin. Δ: A slight amount of liquid component seeped out, or the gel lacked shape retention. ×: Exudation of liquid components was observed or the gel had no shape and could not be applied to the skin as a gel.

[0039] (Test Example 2: Appearance) The appearance of each of the preparations of Examples 1 to 4 and Comparative Example 1 was observed after standing for 12 hours after production. The appearance of each preparation was evaluated according to the following criteria. The results are shown in Tables 1 and 2. ◯: No lidocaine crystallization was observed. △: A small amount of lidocaine crystals were observed in the preparation. ×: Lidocaine crystals precipitated in the preparation.

[0040] In the gel preparations of the present invention, although slight exudation of liquid components was observed in the preparation of Example 4, no crystal precipitation was observed and the shape retention was good. On the other hand, in the gel preparation of Comparative Example 1, slight exudation of liquid components was observed in the gel properties, and further, crystals of lidocaine were precipitated after production.

[0041] Comparative Example 2 A formulation of Comparative Example 2 was produced using the "10% lidocaine ointment" prescribed in the hospital as a reference. The composition of the formulation is shown in Table 3.

[0042] Comparative Example 3 A formulation of Comparative Example 3 was produced using "10% lidocaine gel" prescribed in the hospital as a reference. The composition of the formulation is shown in Table 3.

[0043] Comparative Example 4 With reference to Example 1 of JP 2021-91655 A, an ethanol-containing gel formulation was produced as a formulation of Comparative Example 4. The composition of the formulation is shown in Table 3.

[0044] [Table 3]

[0045] (Test Example 3: Drug Efficacy Test) A pinprick test was carried out using the preparations of Example 1 and Comparative Example 2. The sites where each preparation was applied to three guinea pigs were stimulated with a mandolin wire, and the presence or absence of a spasm reaction was observed. The preparation was repeatedly applied every 2 hours (120 minutes), and the spasm reaction was confirmed without wiping off the drug. If there was no reaction to the stimulation, it was judged to be "effective" and have a local anesthetic effect. The stimulation was given to each guinea pig six times, and the number of no reactions was divided by the number of trials (6 times) to calculate the effectiveness rate (spasm inhibition rate). The results are shown in Figure 1.

[0046] As shown in FIG. 1, it was confirmed that the preparation of Example 1 exhibited superior efficacy (spasm inhibitory effect) compared to the preparation of Comparative Example 2.

[0047] (Test Example 4: Primary skin irritation test in rabbits) A primary skin irritation test was carried out on rabbits for the preparations of Example 1, Comparative Example 2, and Comparative Example 3. Each preparation was applied to the back of a depilated rabbit for 24 hours (open application), and the irritation index (PII) was calculated from the skin symptoms 1 and 48 hours after the preparation was removed. The results and the evaluation criteria are shown in Tables 4 and 5, respectively.

[0048] The gel preparation of the present invention was found to cause less skin irritation and was safer than the various topical preparations prescribed in the hospital.

[0049] [Table 4]

[0050] [Table 5]

[0051] (Test Example 5: In vitro skin permeability test) An in vitro hairless rat skin permeability test was carried out for the gel preparations of Example 1 and Comparative Example 4. The abdominal skin of a male hairless rat (HWY strain, 7 weeks old) was excised and set in a Franz-type diffusion cell, with the dermis side as the receptor side, the inside of which was filled with phosphate buffered saline, and 37°C warm water was circulated through the water jacket. 50 μL of each gel preparation was applied to the epidermis side, and the receptor liquid was sampled 24 hours after the start of the test, and the amount of drug permeated through the skin was measured by high performance liquid chromatography. The cumulative drug permeation amount (μg / cm) after 24 hours was calculated from the measured values. 2 The cumulative drug permeation amount for each formulation over 24 hours after the start of the test is shown in Table 6.

[0052] As shown in Table 6, the preparation of Example 1 was found to have higher skin permeability of lidocaine than the preparation of Comparative Example 4 containing ethanol. This confirmed that the gel preparation of the present invention, even without containing a lower alcohol such as ethanol, has superior drug permeability to preparations containing these alcohols.

[0053] [Table 6] [Industrial Applicability]

[0054] The present invention provides a lidocaine gel that exhibits high percutaneous absorption of lidocaine and low skin irritation. Since the present invention exhibits low irritation even in patients with postherpetic neuralgia, many of whom suffer from skin damage, the gel is extremely effective in improving the patient's QOL.

Claims

1. A gel formulation comprising lidocaine or a pharma- ceutical acceptable salt thereof, a water-soluble polymer, glycerin, and 40% by weight or more of propylene glycol based on the weight of the formulation, and containing no water or C1-4 alcohol.

2. 2. The gel formulation of claim 1, wherein the lidocaine or a pharma- ceutically acceptable salt thereof is a non-salt form of lidocaine.

3. 3. The gel formulation according to claim 1 or 2, wherein the water-soluble polymer is one or more selected from the group consisting of polyacrylic acid, polyacrylates, partially neutralized polyacrylic acids, carmellose sodium, gelatin, methyl vinyl ether-maleic anhydride copolymers, N-vinylacetamide copolymers, sodium alginate, polyvinyl alcohol, polyvinylpyrrolidone, polyvinyl methacrylate, polyethylene oxide, carboxyvinyl polymers, carboxymethyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, starch acrylic acid graft copolymers, carrageenan, sodium alginate, agar, acacia gum, guar gum, xanthan gum, gum arabic, karaya gum, tragacanth gum, and collagen.

4. 3. The gel formulation according to claim 1, wherein the water-soluble polymer is one or more selected from the group consisting of carboxymethyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, methyl cellulose, and ethyl cellulose.

5. 3. The gel formulation according to claim 1 or 2, wherein the water-soluble polymer is hydroxypropyl cellulose.

6. 3. The gel formulation according to claim 1 or 2, comprising, relative to the weight of the formulation, 1 to 20% by weight of lidocaine or a pharma- ceutical acceptable salt thereof, 0.5 to 5% by weight of a water-soluble polymer, 10 to 40% by weight of glycerin, and 40 to 80% by weight of propylene glycol.

7. 3. The gel formulation according to claim 1, wherein the weight ratio of propylene glycol to glycerin is within the range of propylene glycol:glycerin=1:1 to 7:

1.

8. 3. The gel formulation of claim 1 or 2, further comprising one or more additional components selected from the group consisting of 1,3-butanediol, oleic acid, isopropyl myristate, glyceryl triisooctanoate, crotamiton, diethyl sebacate, diisopropyl adipate, and hexyl laurate.

9. 3. The gel formulation of claim 1 or 2, further comprising one or two additional ingredients selected from the group consisting of oleic acid and isopropyl myristate.

10. 9. The gel formulation of claim 8, comprising 0.5 to 15% by weight of the additional ingredient based on the weight of the formulation.

11. 3. The gel formulation of claim 1 or 2 for the induction of local anesthesia, or for the prevention or treatment of arrhythmia or pain.

12. 3. The gel formulation according to claim 1 or 2 for the prevention or treatment of postherpetic neuralgia.

Citation Information

Patent Citations

  • Treatment for pain relating to herpes zoster and postherpetic neuralgia through local ap- plication of local anesthetic

    JP1990300138A

  • Percutaneous absorption tape for local anestasia

    JP1995215850A

  • Water-free patch preparation

    JP2011026227A

  • Topical anesthetic formulation

    US20040131665A1

  • external local anesthetic

    JP2001503035A